Thoma Bravo agreed to acquire a majority of the company. MedeAnalytics’ previous backers Bain Capital Integral Investors and Emergence Capital partners will retain minority stakes.
“MedeAnalytics represents an outstanding investment opportunity in the healthcare data analytics sector,” said Scott Crabill, managing partner at Thoma Bravo.
MedeAnalytics serves more than 1,500 healthcare organizations globally.
More articles on finance issues:
RCM tip of the day: Mitigate spikes in denial rates during the ICD-10 transition
Why HCA is taking the road less traveled when it comes to expansion
CDC: Fewer Americans avoiding medical care due to cost
